Xi'an ruixi Biological Technology Co

Home > Keywords >

Catalog	name	Description	price
R-C-1312	SQ109 CAS：502487-67-4	SQ109 is a drug undergoing development for treatment of tuberculosis.SQ109 showed activity against both drug susceptible and Multi-drug-resistant tuberculosis bacteria,including Extensively drug-resistant tuberculosis strains. In preclinical studies SQ109 enhanced the activity of anti-tubercular drugs isoniazid and rifampin and reduced by >30% the time required to cure mice of experimental TB.SQ109 is being developed by OOO Infectex in Russia and by Sequella Inc internationally.I	price>
R-R-3012	ESI-08 CAS No.301177-43-5	ESI-08/CAS No.301177-43-5 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation.	price>
R-C-1313	Ilomastat (GM6001, Galardin) CAS:142880-36-2	Ilomastat,also known as GM6001 and galardin,is a broad-spectrum matrix metalloproteinase inhibitor with potential anticancer activity.GM6001 is a member of the hydroxamic acid class of reversible metallopeptidase inhibitors. The anionic state of the hydroxamic acid group forms a bidentate complex with the active site zinc.Examples of enzymes that ilomastat inhibit include thermolysin,peptide deformylase,and anthrax lethal factor endopeptidase(LF) produced by the bacterium Bacillus anthracis.	price>
R-R-3013	ASP2453 CAS No.2241719-73-1	ASP2453/CAS No.2241719-73-1 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM.	price>
R-C-1314	AMG337 CAS:1173699-31-4	AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor.AMG 337 inhibits MET kinase activity with an IC50 of<5nM in enzymatic assays.	price>
R-R-3014	Y16 CAS No.429653-73-6	Y16/CAS No.429653-73-6 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP.	price>
R-C-1315	RG2833 (RGFP109) CAS:1215493-56-3	RG2833 is a brain-penetrant HDAC inhibitor with IC50s of 60 nM and 50 nM for HDAC1 and HDAC3,respectively.The Ki values for HDAC1 and HDAC3 are 32 and 5 nM, respectively.	price>
R-R-3015	K-Ras(G12C) inhibitor 12 CAS No.1469337-95-8	K-Ras(G12C) inhibitor 12/CAS No.1469337-95-8 is a K-Ras(G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras(G12C) inhibitor 12 in H1792 cells is 0.	price>
R-C-1316	GSK0660 CAS:1014691-61-2	GSK0660 is a potent PPARβ/δ antagonist with a pIC50 of 6.8(binding assay IC50 =155 nM;antagonist assay IC50=300nM)and is nearly inactive on PPARα and PPARγ with IC50s above approximately 10 μM.GSK0660(100nM)reduces CPT1a(a PPARβ/δ target gene)expression below the basal vehicle-treated level by approximately 50%,but shows no effect on PDK4 expression,which is also a PPARβ/δ target gene in skeletal muscle cells.GSK0660(0.5μM)reduces the levels of AMPK and eNOS phosphorylation,and BMP-2,Runx-2 mRNA expression in MC3T3-E1 cells.	price>
R-R-3016	KRas G12R inhibitor 1	KRas G12R inhibitor 1 (compound 3) is a KRas G12R selective covalent inhibitor that exploits the strong nucleophilicity of mutant cysteines and binds irreversibly in the Switch II region of K-Ras. KRas G12R inhibitor 1 can be used in cancer research.	price>
R-C-1317	APD597 (JNJ-38431055) CAS:897732-93-3	APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes,with EC50 of 46 nM for hGPR119.IC50 value: 46 nM(EC50)Target:hGPR119The design and synthesis of a second generation GPR119-agonist clinical candidate for the treatment of diabetes is described.APD597 was selected for preclinical development based on a good balance between agonist potency,intrinsic activity and in particular on its good solubility and reduced drug-drug interaction potential.	price>
R-R-3017	ZT-12-037-01 CAS No.2328073-61-4	ZT-12-037-01/CAS No.2328073-61-4 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM.	price>
R-C-1318	CH-223191 CAS:301326-22-7	CH223191 is a potent and specific aryl hydrocarbon receptor(AhR)antagonist. CH223191 can prevent 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.2,3,7,8-Tetrachlorodibenzo-p-dioxin(TCDD)is a widespread environmental pollutant with many toxic effects,including endocrine disruption,reproductive dysfunction,immunotoxicity,liver damage,and cancer. CH223191 potently inhibits TCDD-induced AhR-dependent transcription.In addition,CH-223191 blocked the binding of TCDD to AhR and inhibited TCDD-mediated nuclear translocation and DNA binding of AhR.These inhibitory effects of CH-223191 prevented the expression of cytochrome P450 enzymes,target genes of the AhR.CH-223191,may be a useful agent for the study of AhR-mediated signal transduction and the prevention of TCDD-associated pathology.	price>
R-R-3018	KRAS G12D inhibitor 14 CAS No.2765254-39-3	KRAS G12D inhibitor 14/CAS No.2765254-39-3 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D.	price>
R-C-1319	Helioxanthin 8-1 CAS: 840529-13-7	Helioxanthin 8-1 is an analogue of helioxanthin,exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 uM.	price>
R-R-3019	XRP44X CAS No.729605-21-4	XRP44X/CAS No.729605-21-4 inhibits Ras-induced transcription activation with the IC50 of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2. XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules.	price>
R-C-1320	CB5083 CAS:1542705-92-9	CB-5083 is a novel first in class,potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models.	price>
R-R-3020	SAH-SOS1A TFA CAS No.2896737-31-6	SAH-SOS1A TFA/CAS No.2896737-31-6 is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.	price>
R-C-1321	SYM2206 CAS:173952-44-8	SYM2206 is a potent and non-competitive AMPA receptor antagonist,with an IC50 of 1.6 μM.SYM2206 blocks Nav1.6-mediated persistent currents.	price>
R-R-3021	AZD4625	AZD4625 (Compound 21) is a highly potent, selective, covalent and allosteric inhibitor of the mutant GTPase KRASG12C. AZD4625 has high oral bioavailability.	price>

515516517518519520 521522523524525